Anna Truppel-Hartmann

Statistics

Publications

Citations

1.1K

H-Index

Active since

2014

Affiliations

Bristol-Myers Squibb (United States)(Current)

Sarah Cannon

Emory University

Bluebird Bio (United States)

Massachusetts General Hospital

Anna Truppel-Hartmann is an author at Bristol-Myers Squibb (United States) specializing in oncology, multiple myeloma therapy, and hematologic malignancy therapy.

Publications per year

2014–2024

Publications

Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma

Paula Rodríguez‐Otero, Sikander Ailawadhi, Bertrand Arnulf et al. · New England Journal of Medicine · 2023 · 705 citations · Full text

Medicine, Immunology, Oncology +17

Updated Clinical and Correlative Results from the Phase I CRB-402 Study of the BCMA-Targeted CAR T Cell Therapy bb21217 in Patients with Relapsed and Refractory Multiple Myeloma

Noopur Raje, Nina Shah, Sundar Jagannath et al. · Blood · 2021 · 80 citations

Medicine, Hematology, Oncology +16

Ide-cel vs standard regimens in triple-class–exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses

Sikander Ailawadhi, Bertrand Arnulf, Krina K. Patel et al. · Blood · 2024 · 63 citations · Full text

Medicine, Oncology, Immunotherapy +13

KarMMa-2 Cohort 2a: Efficacy and Safety of Idecabtagene Vicleucel in Clinical High-Risk Multiple Myeloma Patients with Early Relapse after Frontline Autologous Stem Cell Transplantation

Saad Z. Usmani, Krina K. Patel, Parameswaran Hari et al. · Blood · 2022 · 51 citations

Medicine, Oncology, Pharmacology +17

Rationale for optimal obinutuzumab/GA101 dosing regimen in B-cell non-Hodgkin lymphoma

Guillaume Cartron, Florence Hourcade‐Potelleret, Franck Morschhauser et al. · Haematologica · 2015 · 36 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

1–5 of 16